What is Pharvaris?
Founded in 2015, Pharvaris is a specialized biopharmaceutical entity headquartered in the Netherlands with a global operational footprint spanning Switzerland and North America. The company is dedicated to the development of novel small molecules designed to treat hereditary angioedema (HAE) and other conditions mediated by B2-receptors. By focusing on oral delivery systems, Pharvaris aims to significantly improve the quality of life for patients who currently rely on invasive treatment modalities. Its market position is defined by its commitment to pharmaceutical research and development for rare disorders, positioning it as a critical player in the evolving landscape of targeted therapeutic interventions.
How much funding has Pharvaris raised?
Pharvaris has raised a total of $365.3M across 4 funding rounds:
Series A
$18.3M
Series B
$66M
Series C
$80M
Stock/Share Issuance
$201M
Series A (2016): $18.3M with participation from Kurma Partners, Idinvest Partners, and Life Sciences Partners
Series B (2019): $66M led by Kurma Partners, venBio Partners, Life Sciences Partners, Venrock Partners, Idinvest Partners, Foresite Capital, and Bain Capital
Series C (2020): $80M supported by venBio Partners, Cormorant Asset Management, Venrock Healthcare Capital Partners, General Atlantic, Viking Global Investors, Bain Capital, and Foresite Capital
Stock/Share Issuance (2025): $201M featuring Leerink Partners, Van Lanschot Kempen, DM Cantor, Oppenheimer, and MORGAN STANLEY
Key Investors in Pharvaris
Kurma Partners
Kurma Partners is a prominent European venture firm specializing in healthcare and biotechnology, focusing on transforming disruptive scientific discoveries into advanced medical solutions for severe diseases.
venBio Partners
venBio is a life sciences investment firm that partners with industry leaders to develop innovative medicines and technologies, focusing on novel therapeutics for unmet medical needs.
Cormorant Asset Management
Cormorant Asset Management is a life sciences investment firm driven by fundamental scientific principles, providing financial resources to support innovative companies in the biotech sector.
What's next for Pharvaris?
With the support of this major strategic investment, Pharvaris is well-positioned to accelerate its clinical programs and expand its research capabilities. The company's strategic roadmap likely involves scaling its development infrastructure to meet the rigorous demands of late-stage clinical trials. By leveraging its deep expertise in B2-receptor science, Pharvaris aims to solidify its competitive advantage in the rare disease market. Future growth will likely focus on navigating regulatory pathways and preparing for the potential commercialization of its lead candidates, ensuring that its innovative oral therapies reach patients with high unmet medical needs globally.
See full Pharvaris company page
